Homocysteine and hypomethylation: A novel link to vascular disease

Trends in Cardiovascular Medicine

Volumn 9, Issue 1-2, 1999, Pages 49-54

  Lee, Mu En ^a   Wang, Hong ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 (2 HYDROXY 3 NONYL)ADENINE; ADENOSINE; CYSTEINE; HOMOCYSTEINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; S ADENOSYLHOMOCYSTEINE;

ARTERIOSCLEROSIS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL REGENERATION; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HUMAN; METHYLATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VEIN THROMBOSIS;

EID: 0033026734     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(99)00002-X     Document Type: Article

References (52)

1. Bester T.H. Methylation meets acetylation. Nature. 393:1998;311-312.
2. Cedar H. DNA methylation and gene activity. Cell. 53:1988;3-4.
3. Celermajer D.S., Sorensen K., Ryalls M.et al. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol. 22:1993;854-858.
4. Clarke S. Protein methylation. Curr Opin Cell Biol. 5:1993;977-983.
5. Creazzo T.L., Godt R.E., Leatherbury L., Conway S.J., Kirby M.L. Role of cardiac neural crest cells in cardiovascular development. Annu Rev Physiol. 60:1998;267-286.
6. Dalton M.L., Gadson P.F. Jr., Wrenn R.W., Rosenquist T.H. Homocysteine signal cascade. production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells FASEB J. 11:1997;703-711.
7. Dudman N.P., Hicks C., Wang J., Wilcken D.E. Human arterial endothelial cell detachment in vitro. its promotion by homocysteine and cysteine Atherosclerosis. 91:1991;77-83.
8. Folsom A.R., Nieto J., McGovern P.G.et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphism, and B vitamins. The atherosclerosis risk in communities (ARIC) study. Circulation. 98:1998;204-210.
9. Hajjar K.A. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest. 91:1993;2873-2879.
10. Hancock J.F., Cadwallader K., Marshall C.J. Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K-ras(B). EMBO J. 10:1991;641-646.
11. Harker L.A., Harlan J.M., Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ Res. 53:1983;731-739.
12. Harpel P.C., Chang V.T., Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin. a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism Proc Natl Acad Sci USA. 89:1992;10,193-10,197.
13. Hayashi T., Honda G., Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood. 79:1992;2930-2936.
14. Iguchi-Ariga S.M., Schaffner W. CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. Genes Dev. 3:1989;612-619.
15. Jain M.K., Layne M.D., Watanabe M.et al. In vitro system for differentiating pluripotent neural crest cells into smooth muscle cells. J Biol Chem. 273:1998;5993-5996.
16. Jakubowski H. Proofreading in vivo. Editing of homocysteine by aminoacyl-tRNA synthetases in Escherichia coli. J Biol Chem. 270:1995;17,672-17,673.
17. Kirby M.L., Waldo K.L. Neural crest and cardiovascular patterning. Circ Res. 77:1995;211-215.
18. Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G. p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma. Blood. 91:1998;1680-1687.
19. Koyama H., Raines E.W., Bornfeldt K.E., Roberts J.M., Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell. 87:1996;1069-1078.
20. Lentz S.R., Sadler J.E. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood. 81:1993;683-689.
21. Lentz S.R., Sobey C.G., Piegors D.J.et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest. 98:1996;24-29.
22. Lipton S.A., Kim W.K., Choi Y.B.et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA. 94:1997;5923-5928.
23. Liu G., Nellaiappan K., Kagan H.M. Irreversible inhibition of lysyl oxidase by ho-mocysteine thiolactone and its selenium and oxygen analogues. Implications for homo-cystinuria. J Biol Chem. 272:1997;32,370-32,377.
24. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest. 98:1996;5-7.
25. Lubec B., Arbeiter K., Hoeger H., Lubec G. Increased cyclin dependent kinase in aortic tissue of rats fed homocysteine. Thromb Haemost. 75:1996;542-545. a.
26. Lubec B., Labudova O., Hoeger H.et al. Homocysteine increases cyclin-dependent kinase in aortic rat tissue. Circulation. 94:1996;2620-2625. b.
27. Majors A., Ehrhart L.A., Pezacka E.H. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol. 17:1997;2074-2081.
28. McCully K.S. Vascular pathology of ho-mocysteinemia. implications for the pathogenesis of arteriosclerosis Am J Pathol. 59:1970;181-194.
29. McCully K.S., Wilson R.B. Homocysteine theory of arteriosclerosis. Atherosclerosis. 22:1975;215-227.
30. Myers B.A., Dubick M.A., Reynolds R.D., Rucker R.B. Effect of vitamin B-6 (pyridoxine) deficiency on lung elastin cross-linking in perinatal and weanling rat pups. Biochem J. 229:1985;153-160.
31. Olszewski A.J., McCully K.S. Homocysteine metabolism and the oxidative modification of proteins and lipids. Atherosclerosis. 97:1992;97-106.
32. Owens G.K. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev. 75:1995;487-517.
33. Parish C. Functional significance of G protein carboxymethylation. Biochemistry. 33:1994;9986-9991.
34. Perna A.F., Ingrosso D., De Santo N.G., Galletti P., Brunone M., Zappia V. Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia. J Am Soc Nephrol. 8:1997;1899-1905.
35. Perna A.F., Ingrosso D., De Santo N.G., Galletti P., Zappia V. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int. 47:1995;247-253.
36. Perna A.F., Ingrosso D., Galletti P., Zappia V., De Santo N.G. Membrane protein damage and methylation reactions in chronic renal failure. Kidney Int. 50:1996;358-366.
37. Philips M.R., Pillinger M.H., Staud R.et al. Carboxyl methylation of Ras-related proteins during signal transduction in neutrophils. Science. 259:1993;977-980.
38. Refsum H., Ueland P.M., Nygard O., Vollset S.E. Homocysteine and cardiovascular disease. Annu Rev Med. 49:1998;31-62.
39. Ross R. The pathogenesis of atherosclerosis. a perspective for the 1990s Nature. 362:1993;801-809.
40. Selhub J., Jacques P.F., Bostom A.G.et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 332:1995;286-291.
41. Selhub J., Jacques P.F., Wilson P.W., Rush D., Rosenberg I.H. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 270:1993;2693-2698.
42. Stamler J.S., Osborne J.A., Jaraki O.et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 91:1993;308-318.
43. Stampfer M.J., Malinow R., Willet W.C.et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 268:1992;877-881.
44. Tate P.H., Bird A.P. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr Opin Genet Dev. 3:1993;226-231.
45. Tawakol A., Omland T., Gerhard M., Wu J.T., Creager M.A. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 95:1997;1119-1121.
46. Tsai J.C., Perrella M.A., Yoshizumi M.et al. Promotion of vascular smooth muscle cell growth by homocysteine. a link to atherosclerosis Proc Natl Acad Sci USA. 91:1994;6369-6373.
47. Tsai J.C., Jain M., Hsieh C.M.et al. Induction of apoptosis by pyrrolidinedithiocarbamate and N-acetylcysteine in vascular smooth muscle cells. J Biol Chem. 271:1996;3667-3670. a.
48. Tsai J.C., Wang H., Perrella M.A.et al. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest. 97:1996;146-153. b.
49. Ueland P.M., Refsum H. Plasma homocysteine, a risk factor for vascular disease. plasma levels in health, disease, and drug therapy Circulation. 87:1993;1107-1113.
50. Upchurch G.R. Jr., Welch G.N., Fabian A.J.et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 272:1997;17,012-17,017.
51. ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem. 272:1997;25,380-25,385.
52. Welch G.N., Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 338:1998;1042-1050.